FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Dendreon cancels GSK Provenge contract

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


After months of poor sales, Dendreon ($DNDN) terminated its Provenge contract with GlaxoSmithKline ($GSK). The pharma giant would have provided the cancer vaccine's antigen through 2015 as part of the deal.

While the total contract value is unknown, Dendreon's original order last year amounted to $8.3 million, due to arrive in August 2011, according to MedCity News. But "no production runs or product batches had been initiated as of September 1, 2011," Dendreon's SEC filing states, "(and) all previously issued product orders were cancelled."

The contract isn't the only collateral damage. Dendreon is expected to announce layoffs and other cost-cutting actions this week as part of a company restructuring plan. Meantime, doctors' reimbursement worries about the firm's $93,000 treatment continue to contribute to Provenge's sluggish start.

The biotech gave its 60-day notice to GSK Sept. 1 and may still pay the drugmaker $4 million until Oct. 31, the contract's end date.

- see the report from MedCity News
- peruse the SEC filing
- read the survey from Sermo

Related Articles:
Medicare panel backs Provenge
Docs blame reimbursement, complexity, cost-benefit for Provenge uptake

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Provenge   Dendreon   GlaxoSmithKline   cancer vaccine